Nervosave Therapeutics
Nervosave Therapeutics is a preclinical French biotech developing AAV9-based gene therapies delivered via perineural injection for peripheral nerve diseases, including Charcot-Marie-Tooth disease type 1A, broader demyelinating CMT, diabetic peripheral neuropathy, and Guillain-Barré syndrome.
- Company typePrivate
- Founded2021
- HeadquartersMontpellier, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nervosave Therapeutics does
Nervosave Therapeutics is a privately held, preclinical French biotechnology company founded in October 2021 in Montpellier by Nicolas Tricaud (CEO/CSO, INSERM researcher and ERC laureate) and Cathy Beaumard (General Manager/Quality Officer). The company is developing a platform of local gene therapies targeting peripheral nerve diseases, with a primary focus on Charcot-Marie-Tooth disease type 1A (CMT1A) and broader demyelinating CMT diseases (CMT1 and CMT4), as well as non-genetic indications including diabetic peripheral neuropathy (DPN) and Guillain-Barré syndrome (GBS). Its core technology is an AAV9-based vector platform delivered via perineural injection, which achieves specific transduction of myelinating Schwann cells and is expected to provide very long-term therapeutic expression (>10 years) of biologics including peptides, mRNA, siRNA, and CRISPR-Cas9.
The pipeline comprises three programs: NVO-101 (AAV vector with siRNA, lead asset for CMT1A), NVO-301 (AAV gene therapy blocking Schwann cell demyelination for all demyelinating CMT diseases), and NVX-401 (peptide-based systemic therapy for DPN and GBS). Preclinical proof of concept has been demonstrated in CMT1A rat models (Gautier et al., 2021), with safety and molecular efficacy confirmed in non-human primates and translatability studies ongoing in sheep. The lead programs target a combined addressable population exceeding 2.5 million patients globally, including >68,000 CMT1A patients near disease onset, ~35 million DPN patients across the US/EU/China, and ~100,000 GBS patients in the US and EU.
Nervosave is pre-revenue and operates without disclosed equity funding; its inflows consist of non-dilutive grants (ERC award to the founder in 2012, MedVallée Boost Invest 2024) and regional incubation support from SATT AxLR, Region Occitanie, and BIC Montpellier. The team has been strengthened with the 2022 appointment of Sarah Abbas, MD, as CMO (clinical development of NVO-101) and the 2023 appointment of Sam Azoulay, MD, MBA, as consulting CEO. The company established an R&D laboratory at Sanofi BioPark Montpellier in February 2023. Its expected revenue model post-approval is one-time licensing or direct commercialization of ATMPs through specialized treatment centers, with potential platform out-licensing to larger pharmaceutical partners.
Nervosave Therapeutics firmographics
Firmographics- Name
- Nervosave Therapeutics
- Legal name
- SAS Nervosave Therapeutics
- Website
- https://nervosavetx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nervosave Therapeutics is a preclinical French biotech developing AAV9-based gene therapies delivered via perineural injection for peripheral nerve diseases, including Charcot-Marie-Tooth disease type 1A, broader demyelinating CMT, diabetic peripheral neuropathy, and Guillain-Barré syndrome.
- Ownership category
- akta.pro rank
Nervosave Therapeutics industry classification
Industry- Product category
- Gene Therapy Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
Keywords
Where Nervosave Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Nervosave Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Gene Therapy Product Sales: As a clinical-stage biotech company developing gene therapies, Nervosave's primary expected revenue stream will come from commercialization of novel therapies for rare neurological diseases, likely through licensing agreements or direct commercialization upon regulatory approval.
- Platform Licensing: Potential for out-licensing platform technology or specific therapeutic candidates to larger pharmaceutical companies for development and commercialization.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Nervosave Therapeutics product offering
Product offeringCore offering
Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse diseases involving peripheral nerves. Its lead candidate NVO-101 is a first-in-class AAV-based gene therapy for Charcot-Marie-Tooth disease type 1A, with NVO-301 extending the approach to broader demyelinating CMT diseases and NVX-401 providing a peptide-based treatment for diabetic peripheral neuropathy and Guillain-Barré syndrome. The platform uses AAV9 vectors delivered through perineural injection to specifically transduce myelinating Schwann cells and achieve long-term therapeutic expression.
Product overview
Nervosave Therapeutics develops a platform of local gene therapies that target peripheral nerve diseases. The portfolio includes three therapeutic products: NVO-101 is an AAV-based gene therapy for Charcot-Marie-Tooth disease 1A (CMT1A), representing the first-in-class local therapy for this indication; NVO-301 is a next-generation AAV gene therapy addressing broader demyelinating CMT diseases (CMT1 and CMT4) by blocking Schwann cell demyelination; and NVX-401 is a peptide-based systemic treatment for Diabetic Peripheral Neuropathy and Guillain-Barré syndrome. The platform leverages AAV9 vectors with perineural injection delivery for localized, long-term therapeutic expression in peripheral nerves.
Differentiator
Problem solved
Functional benefit
Products and services
- NVO-101
Quantifiable outcome
- AAV readily and specifically transduces target cells following local injection in nerves; vector biodistribution mostly restricted to injected nerves with very limited immune response
- +3 more outcomes
Companies that use Nervosave Therapeutics
Customer profileSegments5 records
Ideal customer profiles2 records
Nervosave Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nervosave Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Sanofi BioPark Montpelliercore
- SATT AxLRcore
- Business International Center (BIC) Montpelliercore
- INSERMcore
- Daniel Cohen (Pharnext)minor
Scale indicators8 records
Recent moves7 records
Expansion highlights4 records
Nervosave Therapeutics competitors and assessment
Company assessmentBroad incumbents
- uniQure: Established gene therapy company with AAV-based programs for neurological and rare diseases (e.g., Huntington's, ALS). Overlaps with Nervosave's AAV gene therapy approach to rare neurological disorders.
- Voyager Therapeutics: Clinical-stage AAV gene therapy company with CNS-focused pipeline; comparable on AAV delivery technology and neurological disease focus, though at a more advanced stage.
- Sarepta Therapeutics: Approved gene therapy provider for neuromuscular diseases (e.g., DMD, Elevidys); comparable on rare neuromuscular disease gene therapy commercialization, though at a much larger scale and broader portfolio.
- Regenxbio: Established AAV gene therapy platform company with multiple partnered programs (including neurological indications). Comparable as an AAV-based delivery platform peer, though operating at much broader scale.
Direct peers
- Pharnext: Direct peer: French biotech focused on Charcot-Marie-Tooth disease 1A (PXT-3003), Nervosave's lead indication. Daniel Cohen, former Pharnext CEO, is listed as a Nervosave founding supporter, underlining direct strategic overlap.
- Ionis Pharmaceuticals: Direct peer in CMT1A: antisense oligonucleotide approach targeting PMP22, the same pathophysiology Nervosave's NVO-101 addresses via AAV9-mediated silencing. Competes for the same rare-disease patient pool.
Emerging players
- Helixmith: Emerging player in peripheral neuropathy gene therapy (e.g., Engensis for diabetic peripheral neuropathy), directly overlapping with Nervosave's NVX-401 indication in DPN.
- Passage Bio: Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases; comparable as a peer AAV gene therapy developer targeting rare neurological indications.
- Taysha Gene Therapies: Clinical-stage AAV gene therapy company for rare neurological diseases; comparable platform (AAV-based, rare CNS/PNS, central nervous system focus) and similar pipeline-development stage.
- Genethon: French non-profit gene therapy developer for rare diseases including neuromuscular indications. Nervosave's CMO Sarah Abbas previously led clinical programs at Genethon, making it a direct organizational and therapeutic-area peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Nervosave Therapeutics social profiles
Digital presenceNervosave Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nervosave Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Nervosave Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nervosave Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nervosave Therapeutics
What does Nervosave Therapeutics do?
Nervosave Therapeutics develops a platform of local gene therapies that slow, stop and reverse diseases involving peripheral nerves. Its lead candidate NVO-101 is a first-in-class AAV-based gene therapy for Charcot-Marie-Tooth disease type 1A, with NVO-301 extending the approach to broader demyelinating CMT diseases and NVX-401 providing a peptide-based treatment for diabetic peripheral neuropathy and Guillain-Barré syndrome. The platform uses AAV9 vectors delivered through perineural injection to specifically transduce myelinating Schwann cells and achieve long-term therapeutic expression.
Is Nervosave Therapeutics a public or private company?
Nervosave Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nervosave Therapeutics founded?
Nervosave Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is Nervosave Therapeutics based?
Nervosave Therapeutics is headquartered in Montpellier, France, in the Europe region.
How does Nervosave Therapeutics make money?
Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are platform Licensing.
Who are Nervosave Therapeutics's main competitors?
Broad incumbents on record are uniQure, Voyager Therapeutics, Sarepta Therapeutics and Regenxbio. Direct peers are Pharnext and Ionis Pharmaceuticals. Emerging players are Helixmith, Passage Bio, Taysha Gene Therapies and Genethon.
Does Nervosave Therapeutics have an API?
No public API is recorded for Nervosave Therapeutics.
What industry is Nervosave Therapeutics in?
Nervosave Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its NAICS code is 541714 and its SIC code is 2836.